1.Bone marrow involvement by primary oxalosis
Stefano FRATONI ; Pasquale NISCOLA
Blood Research 2020;55(4):192-192
2.Late but effective long-term response to splenectomy in the treatment of immune thrombocytopenia.
Laura SCARAMUCCI ; Marco GIOVANNINI ; Andrea TENDAS ; Pasquale NISCOLA ; Paolo DE FABRITIIS
Blood Research 2013;48(4):297-298
No abstract available.
Splenectomy*
;
Thrombocytopenia*
3.Primary diffuse large B-cell lymphoma of the bone marrow in a frail and elderly patient successfully treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Pasquale NISCOLA ; Massimiliano PALOMBI ; Stefano FRATONI ; Alessio PERROTTI ; Paolo DE FABRITIIS
Blood Research 2013;48(4):296-297
No abstract available.
Aged*
;
B-Lymphocytes*
;
Bone Marrow*
;
Cyclophosphamide*
;
Doxorubicin*
;
Humans
;
Lymphoma, B-Cell*
;
Prednisone*
;
Vincristine*
;
Rituximab
4.Primary mixed-type autoimmune hemolytic anemia concomitant with acute splanchnic venous thrombosis of idiopathic origin in a young woman: an unexplained association.
Laura SCARAMUCCI ; Marco GIOVANNINI ; Pasquale NISCOLA ; Alessio PERROTTI ; Paolo DE FABRITIIS
Blood Research 2013;48(4):292-293
No abstract available.
Anemia, Hemolytic, Autoimmune*
;
Female
;
Humans
;
Venous Thrombosis*
5.Hematologists and nephrologists working together: moving forward with a new integrated care model for blood-related malignancies?.
Pasquale NISCOLA ; Tommaso CARAVITA ; Paola TATANGELO ; Agostina SINISCALCHI ; Paolo DE FABRITIIS ; Roberto PALUMBO
Blood Research 2017;52(3):218-219
No abstract available.
6.Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Stefano FRATONI ; Paolo DE FABRITIIS
Blood Research 2015;50(2):113-114
No abstract available.
Azacitidine*
;
Humans
7.Concomitant transformation of monoclonal gammopathy of undetermined significance to multiple myeloma and of essential thrombocythemia to acute biphenotypic leukemia 37 years after initial diagnosis.
Pasquale NISCOLA ; Gianfranco CATALANO ; Stefano FRATONI ; Laura SCARAMUCCI ; Paolo DE FABRITIIS ; Tommaso CARAVITA
Blood Research 2013;48(3):228-230
No abstract available.
Leukemia, Biphenotypic, Acute
;
Monoclonal Gammopathy of Undetermined Significance
;
Multiple Myeloma
;
Paraproteinemias
;
Thrombocythemia, Essential
8.Steroid-refractory immune thrombocytopenia in the era of the new thrombomimetic drugs: is there still a role for rituximab?.
Massimiliano PALOMBI ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Malgorzata Monika TRAWINSKA ; Pasquale NISCOLA ; Paolo DE FABRITIIS
Blood Research 2016;51(1):66-66
No abstract available.
Thrombocytopenia*
;
Rituximab
9.Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Marco GIOVANNINI ; Stefano FRATONI ; Paolo DE FABRITIIS
Blood Research 2013;48(2):152-153
No abstract available.
Leukemia, Myelomonocytic, Chronic
;
Myelodysplastic Syndromes
10.Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy.
Pasquale NISCOLA ; Andrea TENDAS ; Laura SCARAMUCCI ; Roberta MEROLA ; Gianfranco CATALANO ; Paolo DE FABRITIIS
Blood Research 2014;49(2):130-137
No abstract available.
Humans
Result Analysis
Print
Save
E-mail